References
Park YA, Kim JM, Kim SA, Min BS, Kim NK, Sohn SK, Lee KY (2010) Totally robotic surgery for rectal cancer: from splenic flexure to pelvic floor in one setup. Surg Endosc 24:715–720
Poon JT, Law WL (2009) Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol 16:3038–3047
Cheung YM, Lange MM, Buunen M, Lange JF (2009) Current technique of laparoscopic total mesorectal excision (TME): an international questionnaire among 368 surgeons. Surg Endosc 23:2796–2801
Katsios GC, Baltogiannis G; Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10(4):473–476
Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality-of-life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350
Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555
Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651
Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696
Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc. 22:1405–1406
Bali C, Ziogas D, Roukos DH, Baltogiannis G (2010) Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. Ann Surg 251:185–186
Glantzounis GK, Roukos DH, Baltogiannis G (2010) Comparative-effectiveness research to standardize retrieved nodes for quality control in colorectal cancer. Ann Surg 252(1):202–203; author reply 203
Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9:227–229
Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9:217–221
Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392
Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27:1337–1338
Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362, author reply 1363
Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681
Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10:123–128
Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995
Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416
Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249:1067–1068
Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16:1771–1782
Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775
Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17
Roukos DH (2010) Novel clinico-genome network modelling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48
Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11:283–287
Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250
Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280; author reply e282–e283
Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Personalized Med 7(4):347–350
Disclosure
Christos Katsios and Georgios Baltogiannis have no conflicts of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katsios, C., Baltogiannis, G. Advances and high demands in totally robotic surgery for rectal cancer. Surg Endosc 25, 1691–1692 (2011). https://doi.org/10.1007/s00464-010-1277-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-010-1277-6